These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 5164105)

  • 1. FDA industry report on safety packaging.
    Verhulst HL; Crotty JJ
    Bull Natl Clgh Poison Control Cent; 1971; ():1-5. PubMed ID: 5164105
    [No Abstract]   [Full Text] [Related]  

  • 2. Child-resistant packaging for certain over-the-counter drug products. Final rule.
    Consumer Product Safety Commission
    Fed Regist; 2001 Aug; 66(149):40111-6. PubMed ID: 11732555
    [TBL] [Abstract][Full Text] [Related]  

  • 3. FDA addresses childhood iron poisoning.
    Am Pharm; 1995 Jan; NS35(1):10. PubMed ID: 7887367
    [No Abstract]   [Full Text] [Related]  

  • 4. Drug safety: the viewpoint of the pharmaceutical manufacturing industry.
    Wigle WW
    Can Med Assoc J; 1968 Feb; 98(6):314-7. PubMed ID: 5636099
    [No Abstract]   [Full Text] [Related]  

  • 5. Effect of safety packaging on aspirin ingestion by children.
    Clarke A; Walton WW
    Pediatrics; 1979 May; 63(5):687-93. PubMed ID: 440889
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tamper-evident packaging requirements for over-the-counter human drug products--FDA. Final rule.
    Fed Regist; 1998 Nov; 63(213):59463-71. PubMed ID: 10187120
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The history and contemporary challenges of the US Food and Drug Administration.
    Borchers AT; Hagie F; Keen CL; Gershwin ME
    Clin Ther; 2007 Jan; 29(1):1-16. PubMed ID: 17379043
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Current good manufacturing practice in manufacturing, processing, packing, or holding of drugs; revision of certain labeling controls--FDA. Final rule.
    Fed Regist; 1993 Aug; 58(147):41348-54. PubMed ID: 10127711
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Iron-containing supplements and drugs; label warning statements and unit-dose packaging requirements; removal of regulations for unit-dose packaging requirements for dietary supplements and drugs. Final rule; removal of regulatory provisions in response to court order.
    Food and Drug Administration, HHS
    Fed Regist; 2003 Oct; 68(201):59714-5. PubMed ID: 14567392
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmaceutical industry in pediatric drug development: partners and collaborators with academia and the FDA.
    Mulberg AE
    J Pediatr Gastroenterol Nutr; 2008 Nov; 47(5):711-3. PubMed ID: 18955888
    [No Abstract]   [Full Text] [Related]  

  • 11. Human and veterinary drugs: good manufacturing practices and proposed exemptions for certain OTC products.
    Fed Regist; 1978 Sep; 43(190 Pt 2):45013-89. PubMed ID: 10316700
    [No Abstract]   [Full Text] [Related]  

  • 12. User-fee boost would up safety, reputations. A new paper suggests that drug makers, FDA can't afford not to raise user fees.
    Med Health; 2005 Oct; 59(39):2, 4. PubMed ID: 16279192
    [No Abstract]   [Full Text] [Related]  

  • 13. New law broadens FDA safety authority, renews user fees.
    Fox JL
    Nat Biotechnol; 2007 Nov; 25(11):1189-90. PubMed ID: 17989653
    [No Abstract]   [Full Text] [Related]  

  • 14. Draft guidance for industry; container and closure integrity testing in lieu of sterility testing as a component of the stability protocol for sterile products; availability--FDA. Notice.
    Fed Regist; 1998 Jan; 63(18):4272-3. PubMed ID: 10177326
    [TBL] [Abstract][Full Text] [Related]  

  • 15. FDA and the life-sciences industry: business as usual?
    Koski G
    Hastings Cent Rep; 2004; 34(5):24-7. PubMed ID: 15553395
    [No Abstract]   [Full Text] [Related]  

  • 16. Child proof packaging.
    Clin Toxicol; 1973; 6(1):153. PubMed ID: 4709569
    [No Abstract]   [Full Text] [Related]  

  • 17. Pharmaceuticals and medical devices: FDA oversight.
    Chaps NA
    Issue Brief Health Policy Track Serv; 2009 Jan; ():1-28. PubMed ID: 19297718
    [No Abstract]   [Full Text] [Related]  

  • 18. FDA proposes more stringent pediatric-use labeling of prescription drug products.
    Clin Pharm; 1993 Jan; 12(1):6. PubMed ID: 8428434
    [No Abstract]   [Full Text] [Related]  

  • 19. Steve Carney talks to Vincent Lee on the pharma industry, the FDA and public education with respect to drugs and their development.
    Lee VH
    Drug Discov Today; 2005 Nov; 10(21):1411-4. PubMed ID: 16243258
    [No Abstract]   [Full Text] [Related]  

  • 20. FDA attempting to overcome major roadblocks in monitoring drug safety.
    Zielinski SL
    J Natl Cancer Inst; 2005 Jun; 97(12):872-3. PubMed ID: 15956645
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.